FIRST QUARTER FINANCIAL RESULTS 2023

Sales for the first quarter ended at MNOK 129.3 (MNOK 116.1), an increase of 11.3%. The Vascular business segment continues the positive development and grows at 21.5% in NOK, currency neutral 8.8% growth. The Imaging products grow at 9.4% in NOK with a currency neutral decline of 3.7%. Currency neutral growth of own products was 2.5%. Operating profit (EBIT) for the quarter ended at MNOK 33.5 (MNOK 33.4). Medistim establishes direct sales organizations in both Canada and China this quarter. Cash position is down MNOK 3.3 due to inventory build up and timing of sales for the quarter. The General Meeting decided a dividend of NOK 4.50 per share, a total dividend payment of MNOK 82.2